Travere Therapeutics has achieved significant operational milestones by reporting its first non-GAAP profitable quarters, driven by accelerating commercial sales of its flagship therapeutic product and disciplined operating expense management.

Travere Therapeutics' primary lead commercial asset is sparsentan, marketed under the brand name Filspari, which represents a groundbreaking targeted therapy approved for the treatment of rare proteinuric kidney diseases such as IgA nephropathy.

Travere Therapeutics does not distribute a cash dividend to its shareholders, resulting in a dividend yield of zero or not applicable.

Travere Therapeutics, traded under the ticker TVTX, is often evaluated by biotech sector analysts as a high-potential yet speculative investment choice.

Analysts monitoring Travere Therapeutics, Inc. (TVTX) maintain a consensus average twelve-month price target hovering around $53.25 to $56.34 per share.

Wall Street equity analysts tracking Trevi Therapeutics, traded under the ticker TRVI, generally issue favorable buy recommendations, driven by promising clinical development updates for its flagship pipeline treatment targeted at chronic cough and r...

Travere Therapeutics, Inc., a prominent biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare diseases, operated previously under the corporate name Retrophin, Inc.

Evaluating whether Travere Therapeutics represents an attractive purchase involves analyzing its transition toward commercial profitability, rare disease drug pipeline execution, and potential market expansion.

Travere Therapeutics, traded publicly on the Nasdaq global market under the ticker symbol TVTX, commands a market capitalization of approximately $5.34 billion.

Travere Therapeutics is a commercial-stage biopharmaceutical enterprise dedicated to identifying, developing, and delivering life-changing therapies for people living with rare, debilitating kidney and metabolic diseases.

BlackRock is an institutional investor in Atlassian Corporation, not its owner. As of early 2026, BlackRock reported beneficial ownership of approximately 5.

The stock ticker TVTX represents the publicly traded corporate shares of Travere Therapeutics, Inc.

Wall Street equity analysts generally track Travere Therapeutics, traded under the ticker TVTX, with favorable buy recommendations rather than sell ratings, driven by strong commercial adoption of its lead rare kidney disease treatment, FILSPARI.

Bristol-Myers Squibb Company (BMY) maintains a forward dividend yield of approximately 4.16%, supported by a regular quarterly cash dividend payout of $0.63 per common share.

Travere Therapeutics, Inc. (TVTX) equity research analysts maintain a consensus Buy rating, with average 12-month price targets highlighting clinical progression and commercialization updates for its flagship rare kidney disease treatments.

Travere Therapeutics, Inc.